revolutionizing The stem cell Transplant PATIENT experience

Magenta is advancing a unique and fully integrated pipeline of product candidates designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.

Stem Cell Mobilization & Collection Program: Our MGTA-145 program is focused on enabling rapid, reliable, predictable and well-tolerated mobilization and collection of sufficient numbers of highly functional stem cells for transplant from both patients and donors.

Targeted Conditioning Program: Our MGTA-117 program is focused on selectively depleting stem cells from patients who are preparing for transplant or gene therapy to make space in the bone marrow for new transplanted stem cells or gene modified cells.  Targeted depletion is designed to reduce the need for high-dose or high-intensity chemotherapy or, in the case of gene therapy applications, to potentially eliminate the need for chemotherapy altogether.

Conditioning Research Platform: Our targeted conditioning research platform seeks to identify and advance the next generation of candidates that selectively deplete stem cells and/or immune cells from a patient prior to transplant, or HSC-based gene therapy. These programs focus on developing products that remove specific cell types, with an approach that is tailored to the patient’s disease and transplant requirements. Initial applications of our research-stage programs include broad conditioning to support both autologous and allogeneic bone marrow transplant, immune reset for autoimmune diseases, and ; lymphodepletion prior to cell therapies such as CAR-T.

Magenta Therapeutics Portfolio